Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation

Condition(s) studied

Investigational drug(s) / intervention(s)

Progestin primed ovarian stimulation: HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.

GnRH antagonist: HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.

Study summary

The aim of this randomized controlled trial is to compare the efficacy and cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in poor responders undergoing double stimulation protocol.

Eligibility

Primary outcome measure(s)

• Medications costs per retrieved oocyte — Ten to fifteen days after starting ovarian stimulation]
  Total cost of medications used in all cycles/number of retrieved oocytes

Trial sites (2)

More Bedaya Hospital trials in Egypt

Other trials for the same condition